RS BioTherapeutics has selected Recipharm, a leading Contract Development and Manufacturing Organization (CDMO), as its partner to conduct product characterization for its investigational compound, RSBT-001. Product characterization is an important next step for RSBT-001 before filing an Investigational New Drug (IND) application with the FDA for the treatment of chronic obstructive pulmonary disease (COPD). In July, RS BioTherapeutics announced positive results from its proof-of-concept study with its development partner Synthonics and Marshall University, for RSBT-001.

RSBT-001 is a patent-pending, nebulized, semi-synthetic, cannabidiolic acid complex in development to address exacerbation and prevent progression of both acute and chronic pulmonary inflammation related to respiratory diseases including COPD, SARS-COV-2, Cystic Fibrosis, Asthma, Bronchitis, and Acute Respiratory Distress Syndrome.